View Older Stories View More Recent Stories

May 17, 2021 10:45AM US Supreme Court denies Sandoz (NVS) petition to review biosimilar Erelzi case
May 17, 2021 10:43AM US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
Feb 16, 2021 01:26PM Novartis (NVS) Granted FDA Approval for Expanded Indication for Entresto in Chronic Heart Failure
Feb 16, 2021 01:22PM Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Sep 22, 2020 08:30AM Novan Inc. and Verrica Pharmaceuticals Participate in Virtual Panel to Discuss Developing Treatments for Molluscum Contagiosum on SNN Network
Sep 16, 2020 02:00PM Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
May 1, 2020 02:48AM Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
Dec 9, 2019 02:52PM Novartis (NVS) says Kymriah demonstrated consistent efficacy and safety outcomes in US patients when used in real-world setting
Dec 9, 2019 02:50PM Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Jun 19, 2019 04:05PM 8x8, Inc. (EGHT) Announces Elizabeth Theophille to Board
Jun 19, 2019 04:05PM 8X8, Inc. Appoints Elizabeth Theophille to Its Board of Directors
Jun 4, 2019 01:03PM Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
Jun 3, 2019 01:19AM Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
May 24, 2019 01:09PM AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
May 23, 2019 07:46PM Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
May 21, 2019 08:00AM Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
Nov 2, 2018 05:27PM Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Oct 29, 2018 02:15AM Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH
Oct 9, 2018 04:55PM Novartis (NVS) says analysis shows crizanlizumab increased number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Oct 9, 2018 04:53PM Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Sep 12, 2018 05:04PM Novartis (NVS) Reports Publication of Landmark PARADIGMS Study Demonstrating Significant Benefit of Gilenya
Sep 12, 2018 05:02PM Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
Jul 18, 2018 12:59PM Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Jul 12, 2018 07:15AM Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
Jun 19, 2018 04:02PM Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
Jun 15, 2018 07:00AM Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
May 30, 2018 07:04AM Novartis (NVS) Says FDA Expedited Review of its drug Promacta for first-line SAA
May 30, 2018 07:00AM FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
May 17, 2018 09:35AM Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
May 11, 2018 06:35PM Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Jan 16, 2018 01:21AM Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
Jan 4, 2018 07:15AM Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Jan 3, 2018 07:15AM Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 11, 2017 11:03AM Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Dec 7, 2017 04:02PM Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis
Dec 6, 2017 01:15PM Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to p
Nov 14, 2017 07:15AM Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Nov 1, 2017 09:14AM Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Oct 31, 2017 09:06AM Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
Oct 31, 2017 09:05AM Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Oct 24, 2017 08:00AM Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
Sep 14, 2017 07:05AM TransCelerate BioPharma Grows Industry Collaboration
Jul 14, 2017 03:52PM Novartis (NVS) Confirms 5 year Data for IL-17A Inhibitor Cosentyx
Jul 14, 2017 03:51PM Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
May 26, 2017 04:02PM Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
May 2, 2017 09:00AM Sandoz Canada launches Sandoz Olmesartan for the treatment of high blood pressure
Apr 18, 2017 09:00AM Sandoz Canada launches Mosaspray(TM) in Quebec: a non-prescription mometasone nasal spray for the treatment of the symptoms of allergic rhinitis
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 6, 2017 06:18AM Novartis (NVS) Says Extension Study of Cosentyx Shows Almost All Psoriasis Patients Regain Skin Clearance Following Treatment Pause
Mar 6, 2017 01:30AM Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
View More Recent Stories View Older Stories